Improve Human Health to Preserve Patients’ Dignity

Leading new drug development for genitourinary tumors & other related diseases

Highlights

Asieris’ APL-2302 Completes First Patient Enrollment in Clinical Trial for Advanced Solid Tumors

Products

Vesique^®(APL-1202) | Cevira^® (APL-1702)

Treatment Areas

Bladder Cancer

Lack of oral therapy for non-muscle invasive bladder cancer (NMIBC) patients with improved patient compliance and less adverse effects from intravesical administration.

Precancerous Cervical Dysplasia

In urgent need of safe and effective options for patients with cervical precancerous lesions, currently treated by traditional surgical methods.

Global Partnership

News & Updates

Asieris’ APL-2302 Completes First Patient Enrollment in Clinical Trial for Advanced Solid Tumors

February 14, 2025

Asieris Presents Phase II Clinical Study Results of APL-1202 in Combined with PD-1 Inhibitor Tislelizumab as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer at 2025 ASCO-GU

January 24, 2025

Asieris Selected as the Top 10 Exhibitors with Communication Influence” in the Innovation Incubation Special Section of the 7th CIIE

January 21, 2025

Asieris Awarded “Annual Star of Innovation” at the 5th Annual Lunjian Awards 2024

January 16, 2025

Asieris Received NMPA IND Approval for a Novel USP1 Inhibitor for the Treatment of Advanced Solid Tumors

January 12, 2025

Asieris Pharmaceuticals Appoints Helen Xu as Chief Commercial Officer

Technology Platform